Format

Send to

Choose Destination
Eur J Surg Oncol. 2017 Oct;43(10):1915-1923. doi: 10.1016/j.ejso.2017.05.009. Epub 2017 May 18.

Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

Author information

1
Department of Pathology, Besançon University Hospital, 3 Boulevard Fleming, F-25030, Besançon, France; University of Bourgogne Franche-Comté, F-25000, Besançon, France. Electronic address: svalmary@univ-fcomte.fr.
2
Department of Pathology, Besançon University Hospital, 3 Boulevard Fleming, F-25030, Besançon, France.
3
Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Hospices Civils de Lyon, F-69000, Lyon, France.
4
Department of Pathology, Claudius Regaud Institute, IUTC Oncopôle, F-31100, Toulouse, France.
5
Department of Pathology, Hautepierre University Hospital, F-67000, Strasbourg, France.
6
Department of Pathology, Baclesse Institute, F-14000, Caen, France.
7
Department of Pathology, Caen University Hospital, F-14000, Caen, France.
8
Department of Pathology, Grenoble University Hospital, F-38000, Grenoble, France.
9
Department of Pathology, Paul Papin Cancer Center, F-49000, Angers, France.
10
Department of Pathology, Bergonie Institute, F-33000, Bordeaux, France.
11
Department of Pathology, Gustave Roussy Institute, F-94000, Villejuif, France.
12
Department of Pathology, Lyon-Sud University Hospital, F-69310, Pierre-Bénite, France.
13
Department of Digestive Surgery, Lyon-Sud University Hospital, F-69000, Lyon, France.
14
Department of Digestive Surgery, Grenoble University Hospital, Grenoble, France.
15
Department of General Surgery, Jean Monnet University Hospital, Saint Étienne, France.
16
Department of Digestive Surgery, Lyon-Sud University Hospital, Lyon, France.
17
Department of Radiology, Claudius Regaud Institute IUTC, Toulouse, France.
18
Department of Radiology, Centre Cardiologique du Nord, Saint Denis, France.
19
Department of Digestive Surgery, Archet 2 University Hospital, Nice, France.
20
Department of Digestive Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France.
21
Department of Surgery, Louis Mourier University Hospital, Colombes, France.
22
Department of Radiology, Grenoble University Hospital, Grenoble, France.
23
Department of Digestive Surgery, Hautepierre University Hospital, Strasbourg, France.
24
Department of Surgical Oncology, Val d'Aurelle Cancer Center, Montpellier, France.
25
Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France.
26
Department of Radiology, Archet 2 University Hospital, Nice, France.
27
Department of Pathology, Archet 2 University Hospital, Nice, France.
28
Department of Digestive Surgery, Poitiers University Hospital, Poitiers, France.
29
Department of Radiology, Lariboisière University Hospital, Paris, France.
30
Department of Radiology, Gustave Roussy Institute, Villejuif, France.
31
Department of Radiology, Lyon-Sud University Hospital, Lyon, France.
32
Department of Surgical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France.
33
Surgical Oncologic & Digestive Unit, Lariboisière University Hospital, Paris, France.
34
Department of Radiology, University Hospital of Toulouse, Toulouse, France.
35
Department of Surgical Oncology, Claudius Regaud Institute IUTC, Toulouse, France.
36
Department of Radiology, Georges Pompidou European Hospital, Paris, France.
37
Department of Digestive Surgery, Estaing University Hospital, Clermont-Ferrand, France.
38
Department of Radiology, ICO René Gauducheau Cancer Center, Saint-Herblain, France.
39
Department of Digestive Surgery, Purpan University Hospital, Toulouse, France.
40
Department of Medical Oncology, Claudius Regaud Institute IUTC, Toulouse, France.
41
Department of Digestive Surgery, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
42
Department of Surgical Oncology, Gustave Roussy Institute, Villejuif, France.
43
Department of Radiology, Hospital of Perpignan, Perpignan, France.
44
Department of Surgical Oncology, Francois Baclesse Comprehensive Cancer Center, Caen, France.
45
Department of Surgical Oncology, Bergonie Institute, Bordeaux, France.
46
Department of Digestive Surgery, Minjoz University Hospital, Besançon, France.
47
Department of Radiology, Robert Debré University Hospital, Reims, France.
48
Department of Radiology, Montpied University Hospital, Clermont-Ferrand, France.
49
Department of Pathology, Lariboisière University Hospital, Paris, France.
50
Department of Digestive Surgery, Robert Debré University Hospital, Reims, France.
51
Department of Radiology, Francois Baclesse Comprehensive Cancer Center, Caen, France.
52
Department of Pathology, Lorraine Institute of Oncology, Vandoeuvre-les-Nancy, France.
53
Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France.
54
Department of Digestive Surgery, Angers University Hospital, Angers, France.
55
Department of Radiology, Curie Institute, Paris, France.
56
Department of Surgical Oncology, Lorraine Institute of Oncology, Vandoeuvre-les-Nancy, France.
57
Department of Surgical Oncology, Curie Institute, Paris, France.
58
Department of Surgery, Léon Bérard Comprehensive Cancer Center, Lyon, France.
59
Gynaecology and Obstetrics Ward, Mother and Child Pole, Poitiers University Hospital, University of Poitiers, Poitiers, France.
60
Department of Digestive Surgical Oncology, University Hospital of Dijon, Dijon, France.
61
INOLA, Lyon, France.
62
Department of Digestive Surgery, Timone University Hospital, Marseille, France.
63
Department of Pathology, Paoli Calmettes Institute, Marseille, France.
64
Department of Digestive Surgery, St Etienne University Hospital, St Etienne, France.
65
Department of Pathology, Francois Baclesse Comprehensive Cancer Center, Caen, France.
66
Department of Medical Oncology, ICO René Gauducheau Cancer Center, Saint-Herblain, France.
67
Department of Pathology, Hospital Saint-Antoine AP-HP, Paris, France.
68
Department of Radiology, Val d'Aurelle Cancer Center, Montpellier, France.
69
Department of Gastroenterology, Nantes University Hospital, Nantes, France.
70
Department of Digestive Surgery, Charles Nicolle University Hospital, Rouen, France.
71
Department of Radiology, Poitiers University Hospital, Poitiers, France.
72
Department of Surgical Oncology, ICO Paul Papin Cancer Center, Angers, France.
73
Department of Digestive and General Surgery, Georges Pompidou European Hospital, Paris, France.

Abstract

BACKGROUND:

Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM.

METHODS:

Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS).

RESULTS:

Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1-5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS.

CONCLUSION:

E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.

KEYWORDS:

Epithelioid subtype; Immunohistochemistry; PD-L1; Peritoneal mesothelioma; Survival

PMID:
28619621
DOI:
10.1016/j.ejso.2017.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center